Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

被引：2
|
作者：
Patel, M. R. [1 ,2 ]
Hamilton, E. P. [2 ]
Piha-Paul, S. A. [3 ]
Henry, J. [4 ]
Banerji, U. [6 ]
Al Hallak, M. N. [5 ,7 ]
Okada, H. [8 ]
Qian, M. [9 ]
Zhang, X. [10 ]
Said, N. [11 ]
Chatikhine, V. [12 ]
Fontana, E. [13 ]
机构：
[1] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA
[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[4] HealthOne, Sarah Cannon Res Inst, Drug Dev Unit, Denver, CO USA
[5] Inst Canc Res, Drug Dev Unit, London, England
[6] Royal Marsden Hosp, London, England
[7] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[8] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA
[9] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[10] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA
[11] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA
[12] Daiichi Sankyo Inc, Early Clin Dev, Basking Ridge, NJ USA
[13] Sarah Cannon Res Inst SCRI UK, Drug Dev, London, England
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
610O
引用
收藏
页码：S488 / S489
页数：2
相关论文
共 50 条
  • [31] Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias
    Garciaz, Sylvain
    Bories, Pierre
    Almeida, Leonor Lopez
    Boher, Jean-Marie
    Belanger, Coralie
    Recher, Christian
    Hermine, Olivier
    Vey, Norbert
    Launay, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias
    Garciaz, Sylvain
    Bories, Pierre
    Boher, Jean-Marie
    Hospital, Marie Anne
    Recher, Christian
    Saillard, Colombe
    Hicheri, Yosr
    Belanger, Coralie
    Monteiro, Renato
    Hermine, Olivier
    Launay, Pierre
    Vey, Norbert
    BLOOD, 2023, 142
  • [33] INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
    Cortes, J.
    DeAngelo, D.
    Wang, E.
    Arana-Yi, C.
    Zweidler-McKay, P.
    Munteanu, M.
    Andreu-Vieyra, C.
    Erba, H.
    Blum, W.
    Traer, E.
    HAEMATOLOGICA, 2017, 102 : 217 - 218
  • [34] Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
    Shapira-Frommer, R.
    Sudo, K.
    Harano, K.
    Mileshkin, L.
    Perets, R.
    Song, M.
    Cohen, J.
    Huang, Y-F.
    Ambrose, H.
    Brier, T.
    Dosani, A.
    Fraenkel, P. G.
    Kmieciak, A.
    Mitchell, P.
    Myers, C.
    Wang, J.
    Odegbami, R. I.
    Sykes, A.
    Turner, S.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S572 - S573
  • [35] A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma
    Infante, Jeffrey R.
    Sandhu, Shahneen K.
    McNeil, Catriona M.
    Kabbarah, Omar
    Li, Chunze
    Zhong, Wei
    Asundi, Jyoti
    Wood, Katie
    Chu, Yu-Waye
    Hamid, Omid
    CANCER RESEARCH, 2014, 74 (19)
  • [36] A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
    Ng, M. C. H.
    Yong, W. P.
    Meric-Bernstam, F.
    Lentz, R. W.
    Srirangam, V.
    Cometa, J. R.
    Blanchard, S.
    Nellore, R.
    Tan, A.
    Lee, Y-A.
    Lim, J.
    Gan, S.
    Koh, C.
    Adanan, Q.
    Joy, J.
    Pendharkar, V.
    Yeong, J. P. S.
    Diermayr, V.
    ANNALS OF ONCOLOGY, 2024, 35 : S516 - S516
  • [37] A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).
    Kamat, Ashish M.
    Lotan, Yair
    Roupret, Morgan
    Steinberg, Gary D.
    Inman, Brant A.
    Powles, Thomas
    Redorta, J. Palou
    Porten, Sima P.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Gorla, Seema Rao
    Haas, Gabriel P.
    Yu, Yao
    Chia, Yen Lin
    Birrenkott, Matthew
    Kates, Max R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
    Day, D.
    Ganju, V.
    Chung, K.
    Si, L.
    Mao, L.
    Aghmesheh, M.
    Hoyer, R.
    Brewin, K.
    Zeng, S.
    Lu, Q.
    Jiang, C.
    Ren, F.
    Wu, X.
    Guo, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S625 - S625
  • [39] DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
    Marathe, O.
    Cheng, Y.
    Spira, A. I.
    Hamilton, E. P.
    Rubinstein, M. M.
    Dong, X.
    Li, L.
    Lv, D.
    Shi, J.
    Gabrail, N.
    Amin, H.
    Wu, C.
    Zhu, Z.
    Qiu, Y.
    Gu, V.
    Qiu, X.
    Shi, R.
    Liu, L.
    Miao, P.
    Ueno, N. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
  • [40] Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
    Peters, S.
    Mathias, C. M. De Cerqueira
    Cheng, M. L.
    Bridges, B.
    Planchard, D.
    Reck, M.
    Soo, R. A.
    Zhu, Y.
    Kim, E.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S875 - S875
12345